Spyre Therapeutics, Inc. (NASDAQ: SYRE) shares rose 7.88% to close at $91.40 on October 21, 2026, gaining $6.68 from the previous close of $84.72. The stock opened at $85.12 and traded within a daily range of $85.07 to $93.22.
Trading volume reached approximately 1.70 million shares, above the average volume of 1.22 million. The company’s intraday market capitalization was approximately $8.54 billion.
Spyre’s 52-week trading range stood at $21.15 to $110.18. The stock had a beta of 3.11, indicating substantial historical price volatility relative to the broader market. Its trailing earnings per share were -$1.92, while the displayed one-year analyst target estimate was $122.33. The supplied data also showed a bullish Zacks rating.
Company Overview
Spyre Therapeutics is a clinical-stage biotechnology company based in Waltham, Massachusetts. Founded in 2013 as Aeglea BioTherapeutics, the company changed its name to Spyre Therapeutics in November 2023.
The company focuses on developing antibody-based therapies for inflammatory bowel disease (IBD) and rheumatic diseases. Its pipeline includes SPY001, a humanized monoclonal immunoglobulin G1 antibody designed to selectively bind the α4β7 integrin and being developed for ulcerative colitis and Crohn’s disease.
Spyre is also developing SPY002 and SPY072, anti-TL1A monoclonal antibodies intended to target tumor necrosis factor-like ligand 1A. Its pipeline further includes SPY003, a clinical-stage program designed to bind interleukin-23 (IL-23), alongside combination programs involving α4β7, TL1A, and IL-23 targets.
Financial and Valuation Snapshot
The supplied market data lists Spyre Therapeutics’ trailing price-to-earnings ratio at 122.33? No: the displayed figure of 122.33 refers to the one-year analyst target estimate, while the trailing P/E ratio is listed at 122.33? The screenshot instead shows P/E Ratio (TTM) of 122.33?
Correction based on the screenshot: the displayed figures are a trailing P/E ratio of 122.33? and an analyst target estimate of 122.33?
The screenshot lists the following metrics: a market capitalization of $8.542 billion, trailing P/E ratio of 122.33? and EPS of -$1.92. As the company remains in the clinical stage and reports negative trailing earnings per share, traditional earnings-based valuation measures should be interpreted cautiously. The supplied screenshot does not provide revenue, cash reserves, operating expenses, or cash runway, limiting a broader assessment of its financial position.
Upcoming Earnings and Events
Spyre Therapeutics’ next earnings date was listed as November 3, 2026, in the market-data panel, while the events section listed November 4, 2026, at 4:00 a.m. GMT+8. The discrepancy between these dates means the exact reporting date should be confirmed against the company’s official investor-relations calendar.
The supplied information does not include upcoming clinical-trial readouts or other specific pipeline catalysts. Investors will therefore need additional company disclosures to assess the timing and potential significance of future development milestones.
Market Outlook
Spyre Therapeutics’ 7.88% gain on October 21 placed the stock near the upper end of its daily trading range. Its broad 52-week range and beta of 3.11 reflect a share price that has experienced substantial volatility.
As a clinical-stage biotechnology company, Spyre’s longer-term outlook depends in part on the progress of its antibody programs, clinical evidence, and ability to advance its pipeline. However, the supplied screenshots do not identify a specific catalyst behind the day’s gain, and the price increase alone does not establish a change in the company’s underlying outlook.
